{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-23-000791","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.525667+00:00","generated_at":"2026-06-15T06:04:13.998135+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Lexaria Bioscience shareholders reelect all 6 director nominees and approve all proposals at annual meeting","bullets":["All six director nominees elected: Bunka (96.5%), Docherty (96.3%), Baxter (74.3%), McKechnie (95.7%), Reese (96.2%), Turkel (97.6%).","Stock option repricing approved with 68.9% of votes cast (1,529,271 for; 677,686 against).","Amendment to Incentive Equity Plan (max shares) approved with 88.6%; evergreen formula addition approved with 63.1%.","Appointment of Malone Bailey LLP as auditors ratified with 96.4% (3,249,199 for).","Ratification of directors' past actions approved with 90.4%."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-23-000791","json":"https://secwatch.observer/filing/0001640334-23-000791.json","markdown":"https://secwatch.observer/filing/0001640334-23-000791.md","text":"https://secwatch.observer/filing/0001640334-23-000791.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/0001640334-23-000791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:04:13.998135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"082c974a76a44ffb10a41d945c672a1c415a6b23","claim":"Lexaria Bioscience Corp. shareholders approved To Appoint Malone Bailey LLP as Auditors at the 2023-05-09 meeting.","evidence_excerpt":"To Appoint Malone Bailey LLP as Auditors 3,249,199 105,067 17,758 96.4%","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/0001640334-23-000791-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-09"}],"fact_type":"shareholder_vote"},{"claim_id":"26f82d7bdcc50c80f28047637b010551dc8d8241","claim":"Lexaria Bioscience Corp. shareholders approved To Approve the Stock Option Repricing at the 2023-05-09 meeting.","evidence_excerpt":"To Approve the Stock Option Repricing 1,529,271 677,686 12,429 1,152,638 68.9%","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/0001640334-23-000791-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-09"}],"fact_type":"shareholder_vote"},{"claim_id":"55e32701c8411e8be28ab3dd53f3ab0bace92baf","claim":"Lexaria Bioscience Corp. shareholders approved To Ratify the lawful actions of the directors for the past year at the 2023-05-09 meeting.","evidence_excerpt":"To Ratify the lawful actions of the directors for the past year 2,005,926 156,382 57,145 1,152,571 90.4%","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/0001640334-23-000791-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-09"}],"fact_type":"shareholder_vote"},{"claim_id":"6403ff625e325dbe07ceccfce0613348b8e16bb7","claim":"Lexaria Bioscience Corp. shareholders approved To Approve the Amendment to the Maxim Number of Shares Issuable pursuant to the Incentive Equity Plan at the 2023-05-09 meeting.","evidence_excerpt":"To Approve the Amendment to the Maxim Number of Shares Issuable pursuant to the Incentive Equity Plan 1,965,779 249,519 4,155 1,152,571 88.6%","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/0001640334-23-000791-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-09"}],"fact_type":"shareholder_vote"},{"claim_id":"813e68937775fb61be0b89c0f66bf1a47a86a846","claim":"Lexaria Bioscience Corp. shareholders approved Election of Directors at the 2023-05-09 meeting.","evidence_excerpt":"To Elect Chris Bunka as a director 2,141,964 77,489 1,152,571 96.5% To Elect John Docherty as a director 2,137,546 81,907 1,152,571 96.3% To Elect Nicholas Baxter as a director 1,648,288 571,165 1,152,571 74.3% To Elect Ted McKechnie as a director 2,123,869 95,584 1,152,571 95.7% To Elect Albert Reese Jr. as a director 2,134,837 84,683 1,152,504 96.2% To Elect Dr. Catherine Turkel as a director 2,165,426 54,027 1,152,571 97.6%","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/0001640334-23-000791-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-09"}],"fact_type":"shareholder_vote"},{"claim_id":"b9b1d2dc0d46428ad95765931fb3a6094df8bdc9","claim":"Lexaria Bioscience Corp. shareholders approved To Approve the Addition of an Evergreen Formula to the Incentive Equity Plan at the 2023-05-09 meeting.","evidence_excerpt":"To Approve the Addition of an Evergreen Formula to the Incentive Equity Plan 1,400,723 709,940 108,790 1,152,571 63.1%","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/0001640334-23-000791-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}